AI Analysis | Feedback

Kodiak Sciences is like a clinical-stage Regeneron, but entirely focused on developing next-generation treatments for major retinal diseases like wet AMD.

Kodiak Sciences is like a specialized biotech, similar to a nascent Amgen or Gilead, but dedicated exclusively to finding new cures for serious eye conditions.

AI Analysis | Feedback

• KSI-301: An anti-vascular endothelial growth factor antibody biopolymer in late-stage clinical trials for treating various retinal diseases such as wet age-related macular degeneration and diabetic macular edema.
• KSI-501: A preclinical bispecific conjugate designed to treat retinal diseases that involve an inflammatory component.
• KSI-601: A preclinical triplet inhibitor being developed for the treatment of dry age-related macular degeneration.

AI Analysis | Feedback

Kodiak Sciences Inc. (KOD) is a clinical stage biopharmaceutical company. Its product candidates, such as KSI-301, KSI-501, and KSI-601, are currently in various stages of clinical development (Phase IIb/III clinical study and preclinical stage). As such, Kodiak Sciences does not yet have approved commercial products on the market and therefore does not have major customers at this time.

AI Analysis | Feedback

• IQVIA Inc. (Symbol: IQV)
• ICON plc (Symbol: ICLR)

AI Analysis | Feedback

Victor Perlroth co-founded Kodiak Sciences in 2009. He previously served as Venture Partner and then Entrepreneur in Residence at MPM Capital, a dedicated healthcare venture capital investment firm. In 2003, Dr. Perlroth co-founded Avidia Inc., a biopharmaceuticals drug discovery and development company, where he served as General Manager and Vice President of Corporate Development. He was one of two principals involved in the acquisition of Avidia by Amgen for $450 million. Earlier in his career, Dr. Perlroth was Chief Operating Officer at Guzik Technical Enterprises.

John Borgeson has over 25 years of pharmaceutical industry experience in finance, strategy, and operations on a global scale. He served as a Vice President of Finance at Pfizer and was a member of Pfizer's Global Financial Leadership Team. His roles at Pfizer included CFO for Pfizer's biotherapeutics division and corporate tax executive with responsibility for the US and Europe. Mr. Borgeson has also led finance for various private biotech companies, including Labrys Biologics, which was acquired by Teva Pharmaceuticals for $825 million. Additionally, he was CFO of venBio, a venture capital firm. He began his career as an auditor with Ernst & Young.

Jason Ehrlich has worked as Global Head of Clinical Ophthalmology at Genentech. He also served as Head Clinician at Lucentis - Genentech.

Dr. Chang serves as the Chief Scientific Officer at Kodiak Sciences.

Almas Qudrat is the Chief Quality Officer at Kodiak Sciences.

AI Analysis | Feedback

Key Risks to Kodiak Sciences (KOD)

1. Clinical Trial Success and Regulatory Approval: Kodiak Sciences' business heavily depends on the successful development, clinical trial outcomes, and regulatory approval of its pipeline candidates, particularly its lead product candidate, tarcocimab tedromer (formerly KSI-301). The company has experienced significant setbacks, such as the failure of KSI-301 to meet its primary endpoint in the Phase 2b/3 DAZZLE study for wet age-related macular degeneration (AMD), which led to a substantial drop in share price. While other trials for different indications are ongoing, the binary nature of clinical trial results and potential delays or failures in obtaining regulatory approval for any of its drug candidates pose a fundamental risk to the company's future growth and commercialization prospects.
2. Intense Competition in the Retinal Disease Market: Kodiak Sciences operates in a highly competitive biopharmaceutical market for retinal diseases. Major established pharmaceutical companies, such as Regeneron (with Eylea and Eylea HD), Novartis (with Lucentis), and Roche (with Vabysmo), already have significant market share with approved and widely adopted therapies. The success of Kodiak's products, even if approved, will depend on their ability to differentiate themselves and compete effectively against these entrenched treatments and other emerging therapies, which could impact market share, pricing power, and profitability.
3. Financial Risks and Dependence on External Funding: As a clinical-stage biopharmaceutical company with no current revenue-generating products, Kodiak Sciences is unprofitable and incurs ongoing losses due to significant research and development expenses. The company relies on external funding to support its operations and advance its clinical programs. Any challenges in securing future financing, or if clinical outcomes or financing options disappoint, could lead to further dilution for shareholders and impact the company's ability to continue its development activities.

AI Analysis | Feedback

The following clear emerging threats have been identified for Kodiak Sciences:

• Vabysmo (faricimab) from Roche/Genentech: Approved in 2022, Vabysmo is a dual anti-VEGF/anti-Ang-2 antibody that offers extended durability for wet age-related macular degeneration (AMD) and diabetic macular edema (DME), allowing for treatment intervals up to four months. Kodiak's lead product candidate, KSI-301, is an anti-VEGF antibody biopolymer primarily differentiated by its goal of extended durability. Vabysmo's established efficacy and extended durability profile directly competes with and sets a significant benchmark for KSI-301, posing a clear threat to its potential market adoption and commercial success if it cannot demonstrate a superior profile.

• Recently approved treatments for geographic atrophy (dry AMD): Syfovre (pegcetacoplan) from Apellis Pharmaceuticals and Izervay (avacincaptad pegol) from Iveric Bio were the first two drugs approved for geographic atrophy (a form of dry AMD) in 2023. While Kodiak has a preclinical stage product candidate, KSI-601, for the treatment of dry AMD, the approval and commercialization of these two drugs establish an entrenched market presence and set performance expectations for any future dry AMD treatments. This creates a significant competitive barrier and threat for Kodiak's much earlier-stage candidate aiming to enter the same therapeutic area.

AI Analysis | Feedback

The addressable markets for Kodiak Sciences' main products are as follows:

• KSI-301 is in clinical study to treat:
  • Wet age-related macular degeneration (AMD): The global market for wet age-related macular degeneration was valued at approximately USD 9.4 billion in 2024.
  • Diabetic macular edema: The global diabetic macular edema treatment market is valued at approximately USD 5 billion in 2024.
  • Naïve macular edema due to retinal vein occlusion: The global retinal vein occlusion market size was calculated at USD 2.82 billion in 2024.
  • Non-proliferative diabetic retinopathy: The global non-proliferative diabetic retinopathy market size was USD 2.62 billion in 2024.
• KSI-501 is a preclinical stage product candidate to treat retinal diseases with an inflammatory component. The specific addressable market size for this product is not available in the provided information.
• KSI-601 is a triplet inhibitor for the treatment of dry AMD: The global dry age-related macular degeneration market was valued at USD 5.27 billion in 2024.

AI Analysis | Feedback

Kodiak Sciences Inc. (KOD), a clinical-stage biopharmaceutical company, currently generates no product revenue and its future revenue growth is entirely contingent upon the successful development, regulatory approval, and commercialization of its pipeline assets. Over the next 2-3 years, the expected drivers of future revenue growth for Kodiak Sciences are centered on the launch and market penetration of its late-stage product candidates:

1. Commercialization of Tarcocimab Tedromer (KSI-301) for Retinal Vascular Diseases: Kodiak's lead product candidate, tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer, is in late-stage clinical development for several high-prevalence retinal diseases. Positive topline data readouts from its Phase 3 GLOW2 study in diabetic retinopathy (expected in Q1 2026) and the DAYBREAK study in wet age-related macular degeneration (wet AMD) (expected in Q2 2026) are anticipated to lead to the submission of a Biologics License Application (BLA) covering multiple indications, including wet AMD, diabetic retinopathy, and retinal vein occlusion. The potential for extended dosing intervals with tarcocimab is a key differentiator in the substantial anti-VEGF market.

2. Commercialization of KSI-501 for Wet AMD and Retinal Vascular Diseases with an Inflammatory Component: KSI-501, a bispecific anti-IL-6 and VEGF-trap therapy, is also being evaluated in the Phase 3 DAYBREAK study for wet AMD, with topline data expected in 3Q 2026. This candidate aims to provide enhanced efficacy and durability by simultaneously targeting both VEGF-mediated vascular permeability and IL-6 mediated inflammation, addressing a broader range of disease biology beyond just VEGF inhibition.

3. Commercialization of KSI-101 for Macular Edema Secondary to Inflammation (MESI): Kodiak is developing KSI-101, a bispecific protein, for the treatment of Macular Edema Secondary to Inflammation (MESI), which represents a "greenfield market opportunity" as there are currently no available intravitreal biologic therapies specifically addressing the spectrum of MESI diseases. Phase 3 studies (PEAK and PINNACLE) are actively enrolling, with topline data expected in 4Q 2026 and 1Q 2027, respectively. Successful commercialization in this underserved market could open up a new revenue stream for the company.

AI Analysis | Feedback

Share Issuance

• Kodiak Sciences completed an underwritten public offering in December 2025, selling 8,000,000 common shares at $23.00 per share, including the full exercise of underwriters' option, generating approximately $184 million in gross proceeds.
• This offering was an expansion from an initial plan to raise around $160 million through the sale of 6,956,522 shares, with an option for additional shares for underwriters.
• The capital raised from these issuances is intended to fund late-stage clinical trials for its portfolio and extend the company's cash runway, with the December 2025 offering extending it into the second half of 2027.

Inbound Investments

• In the fourth quarter of 2025, Baker Bros. Advisors increased its stake in Kodiak Sciences by 2,608,696 shares, representing an estimated $53.42 million investment.
• During the same period, Connecticut-based Braidwell established a new position in Kodiak Sciences, acquiring 2,072,788 shares with an estimated value of $57.96 million.
• Baker Bros. Advisors maintains a significant ownership interest in Kodiak Sciences, holding 33% after the secondary offering in late 2025.

Capital Expenditures

• Kodiak Sciences reported $60,000 in capital expenditures for Q3 2025, which marked a 54.9% decrease from the previous quarter.
• The company's latest reported capital expenditure for the last twelve months (LTM) as of July 2025 was $12.2 million.
• Capital expenditures are primarily focused on funding long-term assets and infrastructure essential for the company's drug discovery, preclinical development, clinical trials, and manufacturing activities.